文献速递妇科

帕唑帕尼联合口服节拍化疗治疗铂耐药/难治性上皮性卵巢癌的II期随机对照试验

Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
PubMed 文献 · Gynecol Oncol · 2021-06-02

结果显示B组中位无进展生存期显著延长(5.1个月 vs 3.4个月,p=0.045),中位总生存期B组未达到而A组为11.2个月(p=0.032),不良反应可耐受。

要点

  • 帕唑帕尼联合节拍化疗显著改善铂耐药/难治性EOC的PFS和OS。
  • 联合方案不良反应可耐受,口腔黏膜炎和乏力在B组略多但无统计学差异。
  • B组生活质量症状量表有适度改善。

核心结论

  • 在依托泊苷和环磷酰胺的节拍化疗基础上加用帕唑帕尼,可能成为铂耐药/难治性上皮性卵巢癌的一种新型口服联合节拍治疗方案。

研究设计与样本

  • A组(n=38)接受口服依托泊苷50 mg第1-14天、环磷酰胺50 mg第1-28天,每4周重复;B组(n=37)在此基础上加用帕唑帕尼400 mg每日一次。
  • 主要终点为无进展生存期(PFS),次要终点为总生存期(OS)、毒性和生活质量(EORTC问卷)。

主要发现

  • B组中位PFS为5.1个月(95% CI 3.13-10.33),A组为3.4个月(95% CI 3.0-6.53),p=0.045。
  • B组中位OS未达到,A组为11.2个月(95% CI 5.66-未达到),p=0.032。
  • 口腔黏膜炎(p=0.36)和乏力(p=0.08)在B组更常见,但差异无统计学意义。
  • B组生活质量症状量表有适度改善。
  • 两组血清VEGF和PDGF水平随治疗下降(A组p<0.0001,B组p<0.016)。

临床怎么用

  • 对于铂耐药/难治性上皮性卵巢癌,可考虑在依托泊苷和环磷酰胺节拍化疗基础上加用帕唑帕尼,以改善PFS和OS。
  • 治疗期间需关注口腔黏膜炎和乏力等不良反应,并监测生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of patients with platinum resistant/refractory epithelial ovarian cancer (EOC) is an unmet need. We evaluated the role of oral metronomic therapy in this setting. PATIENTS AND METHODS: Between October 2017 and September 2019 seventy five patients with platinum resistant/refractory EOC were enrolled. Patients received oral etoposide (50 mg, day 1 to 14, cyclophosphamide 50 mg, day 1 to 28, every 4 weeks (Arm A, n = 38). Patients in Arm- B (n = 37) received Pazopanib (400 mg once daily) in addition to etoposide and cyclophosphamide. Quality of life (QoL) was evaluated using the EORTC questionnaire. Serum VEGF and PDGF were estimated at baseline, after 3rd and 6th cycle. The primary endpoint was progression free survival (PFS). Secondary endpoints were overall survival (OS), toxicity and QoL. RESULTS: Patients characteristics were well matched. Median PFS was higher in arm B, 5.1 months (95% CI 3.13 to10.33) compared to 3.4 months (95% CI 3.0 to 6.53) in arm A, p = 0.045. Median OS has 'not reached' in Arm B compared to 11.2 months (95% CI, 5.66 - not reached) in arm A, p = 0.032. Therapy was tolerated well; oral mucositis (p = 0.36) and fatigue (p = 0.08) being more in arm B. QoL assessment revealed modest improvement in 'symptom scales' in Arm B. Serum VEGF and PDGF levels decreased with therapy in both arms (Arm A-p < 0.0001, Arm B-p < 0.016). CONCLUSION: Addition of pazopanib to etoposide and cyclophosphamide could be a novel oral combination for metronomic therapy for platinum resistant/refractory EOC. TRIAL REGISTRATION: CTRI/2017/10/010219.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sharma A, Singh M, Chauhan R, et al. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial. Gynecol Oncol. 2021. PMID: 34088513. doi:10.1016/j.ygyno.2021.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。